Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?  

We have been offering NAE to patients with lower grade, lower Ki-67% and strongly ER/PR+ breast cancers. The selection of NAE vs primary surgery is typically being determined on the basis of patient age and co-morbidity (e.g. the greater we believe the patient's risk from contact with the healthcare...